Malignant melanoma comprises just 3% of skin cancers, but is the most deadly form of this type of cancer, accounting for about 80% of all skin cancer deaths. This feature discusses the immunotherapeutic approach to melanoma treatment, and describes the various products that are under development, and the associated deals. The products include: Oxford BioMedica#8217;s recombinant vector vaccine Hi-8#174; MEL; Vical#8217;s vaccine Allovectin-7#174;, a gene therapy vaccine product; and vaccines from Antigenics, GlaxoSmithKline, CSL, IDM Pharma and AVAX Technologies.